These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25330770)

  • 1. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
    Liu JC; Voisin V; Wang S; Wang DY; Jones RA; Datti A; Uehling D; Al-awar R; Egan SE; Bader GD; Tsao M; Mak TW; Zacksenhaus E
    EMBO Mol Med; 2014 Dec; 6(12):1542-60. PubMed ID: 25330770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN.
    Russnes HG; Caldas C
    EMBO Mol Med; 2014 Dec; 6(12):1512-4. PubMed ID: 25471453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
    Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
    Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
    Ju Y; Ben-David Y; Rotin D; Zacksenhaus E
    Sci Rep; 2021 Apr; 11(1):9181. PubMed ID: 33911160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.
    Gasparyan M; Lo MC; Jiang H; Lin CC; Sun D
    J Biol Chem; 2020 Aug; 295(34):12188-12202. PubMed ID: 32467227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
    Kim G; Ouzounova M; Quraishi AA; Davis A; Tawakkol N; Clouthier SG; Malik F; Paulson AK; D'Angelo RC; Korkaya S; Baker TL; Esen ES; Prat A; Liu S; Kleer CG; Thomas DG; Wicha MS; Korkaya H
    Oncogene; 2015 Feb; 34(6):671-80. PubMed ID: 24531711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
    Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
    Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
    BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 13. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
    Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
    Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
    Pires MM; Hopkins BD; Saal LH; Parsons RE
    Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice.
    Yang Y; Wang J; Wan J; Cheng Q; Cheng Z; Zhou X; Wang O; Shi K; Wang L; Wang B; Zhu X; Chen J; Feng D; Liu Y; Jahan-Mihan Y; Haddock AN; Edenfield BH; Peng G; Hohenstein JD; McCabe CE; O'Brien DR; Wang C; Ilyas SI; Jiang L; Torbenson MS; Wang H; Nakhleh RE; Shi X; Wang Y; Bi Y; Gores GJ; Patel T; Ji B
    J Hepatol; 2024 Jul; 81(1):120-134. PubMed ID: 38428643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Chai C; Wu HH; Abuetabh Y; Sergi C; Leng R
    Cancer Lett; 2022 Feb; 527():41-48. PubMed ID: 34902523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
    Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
    J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
    Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
    J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.